Key facts
- Healionics’s last known valuation is $44.5M (Dec 2025).
- It has raised $28.2M across 4 recorded rounds; the latest was Seed Round ($2.0M) in Dec 2025.
- Notable investors include MedTech Innovator, National Institutes of Health, New York Angels, Band of Angels, iSelect Fund — 41 tracked in total.
- Healionics has filed 9 Form Ds with the SEC since 2011, most recently Feb 2024 ($5.5M sold to 70 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 41 names
- ·Watchlist + deal alerts for Healionics
Funding rounds
4 roundsAbout Healionics
Developer of vascular graft technology designed to improve blood access for dialysis in patients with kidney failure. The company offers a synthetic blood vessel that reduces the risk of occlusion and infection commonly associated with existing grafts by leveraging a biomaterial scaffold that enables the formation of new blood vessels and healing while reducing foreign body response, minimizing tissue scarring, and imparting high resistance to infection, allowing healthcare providers to deliver safer, more reliable, and cost-effective dialysis treatment.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2007
- Employees
- 10
- Website
- healionics.com/
- Ownership
- Privately Held (backing)
Healionics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Healionics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Healionics in its N-PORT filings yet. We sweep new filings monthly.